Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00774943
First received: October 16, 2008
Last updated: April 5, 2013
Last verified: April 2013

October 16, 2008
April 5, 2013
December 2008
May 2012   (final data collection date for primary outcome measure)
Subject incidence of treatment-emergent adverse events and the incidence of antibodies to AMG 557. [ Time Frame: Throughout study period ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00774943 on ClinicalTrials.gov Archive Site
Serum PK profile of AMG 557 after multiple dose administrations. Biomarkers of pharmacodynamic activity for AMG 557. [ Time Frame: Throughout study period ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Systemic Lupus Erythematosus
Drug: AMG 557
A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
  • Active Comparator: AMG 557
    Intervention: Drug: AMG 557
  • Placebo Comparator: Placebo
    Intervention: Drug: AMG 557
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Before any study-specific procedure, the appropriate written informed consent must be obtained;
  • Men and women, between the ages of 18 and 70 years old, inclusive, at the time of randomization;
  • Diagnosis of SLE as defined by the most recent ACR criteria, including a positive ANA at screening or documented positive ANA (the titer should be at least 1:80) in the past.
  • SLE duration of at least six months, as diagnosed by a physician;
  • Stable disease, defined as no change in SLE therapy within the previous 30 days; and, in the opinion of the investigator, no anticipated need for a change in SLE therapy will be required while the subject is enrolled in the study;
  • Normal or clinically acceptable ECG (12-lead reporting ventricular rate and PR, QRS, QT, QTc) at screening and Day -1 based on the opinion of the investigator;
  • Body mass index from 18 to 40 kg/m2 at screening;
  • Able and willing to complete entire study according to study schedule.
  • Immunizations up to date, with a minimum of tetanus, diphtheria, pertussis (td/Tdap), pneumococcal (polysaccharide) and influenza (during flu season) vaccinations, as determined by the Principal Investigator.

Exclusion Criteria:

  • Positive serology for HIV antibodies, hepatitis B surface antigen or hepatitis C antibodies (confirmed by PCR or RIBA);
  • Have had signs or symptoms of a viral, bacterial or fungal infection within 30 days of study randomization;
  • Evidence of active or latent tuberculosis as assessed by PPD or Quantiferon testing at screening;
  • Have donated blood or experienced a loss of blood >500mL within 4 weeks of randomization;
  • History of ethanol or drug abuse within the last one year prior to randomization;
  • Evidence of significant renal insufficiency, defined by:

The glomerular fitration rate < 50 mL/min using the Cockroft and Gault equation;

  • Evidence of liver disease (eg, serum ALT or AST > 2x upper limit of normal);
  • Total WBC <3000 x 106/L;
  • Neutrophil count < 1500 x106/L
  • Platelet count <75,000 x 106/L
  • Hemoglobin <10g/dL
  • Any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of SLE) that would, by it progressive nature and/or severity, interfere with the study evaluation, completion and/or procedures in the medical judgment of the investigator. This includes any age related co-morbidites such as presence of congestive heart failure, angina, chronic obstructive pulmonary disease, asthma, and malignancies (other than resected squamous and basal cell carcinoma of the skin).
  • Presence or history of vasculitis (comprising internal organs or extremities or leading to peripheral neuropathy) within the last 3 years, presence or history of active CNS lupus (defined as seizure disorder, cerebral vascular accident, psychosis ascribed to SLE , encephalitis, meningitis, and myelitis) requiring therapy within the last 3 years;
  • Uncontrolled hypertension (Blood pressure > 150/95);
  • Poorly controlled diabetes (HbA1c > 8%);
  • Any history of granulomatous disease including autoimmune granulomatous vasculitis and sarcoidosis;
  • Underlying condition that predisposes the subject to infections (eg, history of splenectomy);
  • Any disorder or condition that prevents the subject from providing truly informed consent;
  • Prior administration of any other biologic that primarily targets the immune system (eg, Lymphostat-B, TACI-Ig, or CTLA4-Ig) in the past 9 months. This includes prior administration of AMG 557;
  • Presence of AMG 557 anti-bodies;
  • Prior administration of rituximab > 9 months with CD19+ B cells <5/µL;
  • Administration of cyclophosphamide (or any other alkylating agent), cyclosporine, tacrolimus, or sirolimus, or > 100 mg/day prednisone or equivalent in the 6 months prior to randomization;
  • Participated in an investigational drug trial involving a monoclonal antibody (not targeting the immune system) within 3 months or 5 half-lives, whichever time period is longer, prior to randomization;
  • Participated in any another investigational drug or device trial within the previous 30 days or 5 half-lives, whichever time period is longer, prior to randomization;
  • Administration of >10 mg/day prednisone (or equivalent) in the 30 days prior to randomization;
  • Known sensitivity to mammalian derived products;
  • Unwilling to practice an effective method of double-barrier contraception as determined by the investigator for the duration of the study;
  • Positive serum hCG at screening or positive urine hCG on D-1; or females who are currently lactating;
  • Known allergies to shellfish or any excipients found in KLH;
  • Previous immunization with KLH.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00774943
20060169
Not Provided
Amgen
Amgen
Not Provided
Study Director: MD Amgen
Amgen
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP